NCT05618366View on ClinicalTrials.gov

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 7, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Lymphoma, Non-HodgkinDiffuse Large B Cell LymphomaFollicular Lymphoma
Interventions
DRUG

Venetoclax

Participants will receive oral venetoclax taken once per day. The dose will be between 200 and 800 mg daily, with the exact dose determined by the protocol.

DRUG

Tazemetostat

Tazemetostat 800mg taken orally, twice daily.

Trial Locations (1)

10021

RECRUITING

Weill Cornell Medicine/NewYork-Presberteryian Hospital, New York

Sponsors
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Epizyme, Inc.

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER